MedTrace Logo

Rasburicase in Tumor Lysis Syndrome

NCT00302653 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2009-09-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

Conditions

  • Hyperuricemia

Interventions

DRUG

Rasburicase

Rasburicase 0,20mg/Kg/Day once a day 3-7 days

Sponsors & Collaborators

Principal Investigators

  • Jaderson Lima · Sanofi-aventis administrative office Brazil

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302653 on ClinicalTrials.gov